CancerFax
person
verifiedCancerFax Verified
schoolM.D., Ph.D.

Dr.ย Yeon Heeย Park

M.D., Ph.D.

Professor, Department of Hematology-Oncology

corporate_fareSamsung Medical Center, Seoul

check_circleBreast Cancer
check_circleCDK4/6 Inhibitor Research
check_circleMetastatic Breast Cancer
check_circleClinical Trial Director
INSTITUTION
corporate_fareSamsung Medical Center
DEPARTMENT
scienceHematology-Oncology / Breast Cancer Centre
SPECIALTY
medical_servicesBreast Cancer Medical Oncology
LOCATION
location_onSeoul, South Korea
INTERNATIONAL PATIENTS
publicInternational Patients Welcome
person

Yeon Hee Park

M.D., Ph.D.

Prof. Yeon Hee Park is a Professor in the Department of Hematology-Oncology at Samsung Medical Center and Sungkyunkwan University School of Medicine in Seoul, South Korea. She is a specialist in breast cancer medical oncology, with over 25 years of clinical and academic experience in the systemic treatment of breast cancer. Samsung Medical Center lists her clinical expertise as breast cancer and identifies her specialty group as the Breast Cancer Centre.

Prof. Park's career has centred on the management of advanced and metastatic breast cancer, with particular focus on hormone receptor-positive, HER2-positive, and triple-negative subtypes, including breast cancer in premenopausal women. She has held successive leadership roles at Samsung Medical Center, serving as Secretary of the Breast Cancer Centre, Director of the Breast Cancer Centre from 2017 to 2021, and currently Director of the Clinical Trial Centre since 2021. Her postdoctoral training was completed at UCSD Cancer Center and the Sidney Kimmel Cancer Center in San Diego. Sungkyunkwan University attributes 389 research outputs, an h-index of 63, and more than 26,000 citations to her academic profile, placing her among the most-cited breast cancer researchers at the institution.

workspace_premium25+Years Experience
calendar_month
M
Visiting Days
public
International Patients

Samsung Medical Center provides English-language appointment and international patient contact information. CancerFax can coordinate medical record review and consultation support for international patients seeking an opinion from Prof. Park, subject to hospital availability and case acceptance.

stars

Why Consider Prof. Yeon Hee Park?

Prof. Park combines focused clinical expertise in breast cancer with one of the most active research profiles in Korean oncology. Her dual role as a treating oncologist and Director of the Clinical Trial Centre at Samsung Medical Center offers patients access to both established and investigational treatment approaches.

emoji_events
Breast Cancer Programme Leader
Prof. Park served as Director of the Breast Cancer Centre at Samsung Medical Center from 2017 to 2021 and currently directs the Clinical Trial Centre, reflecting over a decade of programme leadership at one of South Korea's major tertiary cancer hospitals.
science
CDK4/6 and Novel Therapy Research
Prof. Park is the principal investigator of the Young-PEARL study, a randomised phase II trial comparing palbociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal HR-positive, HER2-negative metastatic breast cancer, with updated survival results presented at the 2024 ASCO Annual Meeting.
menu_book
Highly Cited Researcher
Sungkyunkwan University reports 389 research outputs, an h-index of 63, and more than 26,000 citations for Prof. Park's academic profile, spanning breast cancer, metastatic disease, triple-negative breast cancer, and modern systemic therapies including antibody-drug conjugates.
language
International Patient Access
Samsung Medical Center maintains an English-language international patient services infrastructure. CancerFax can assist international patients in organising records, preparing case summaries, and navigating the appointment process.
verified_user

Areas of Specialisation

Prof. Park's clinical and research focus is breast cancer medical oncology across all major molecular subtypes, with particular expertise in advanced and metastatic disease.

Prof. Yeon Hee Park specialises in the systemic treatment of breast cancer, covering hormone receptor-positive, HER2-positive, triple-negative, and young-age breast cancer. Her clinical expertise is complemented by an extensive research programme in modern breast cancer therapeutics.

Treatment Specialties

Hormone Receptor-Positive Breast Cancer

Endocrine therapy and CDK4/6 inhibitor-based strategies for premenopausal and postmenopausal patients with HR-positive, HER2-negative disease.

starsEndocrine Therapy
  • arrow_rightAromatase inhibitor-based regimens for postmenopausal patients
  • arrow_rightGnRH agonist strategies for ovarian function suppression in premenopausal disease
  • arrow_rightExemestane plus GnRH agonist combinations in metastatic disease
starsCDK4/6 Inhibitor-Based Treatment
  • arrow_rightPalbociclib-based combination treatment planning for eligible patients
  • arrow_rightPremenopausal HR-positive metastatic breast cancer treatment, including Young-PEARL study protocols
  • arrow_rightBiomarker-informed treatment selection for advanced disease

HER2-Positive and Triple-Negative Breast Cancer

Anti-HER2 therapy, antibody-drug conjugates, immunotherapy, and chemotherapy for HER2-positive and triple-negative subtypes.

starsAnti-HER2 and Antibody-Drug Conjugate Therapy
  • arrow_rightTrastuzumab deruxtecan and other HER2-targeted agent research and clinical application
  • arrow_rightSacituzumab govitecan research in breast cancer
  • arrow_rightTreatment planning for HER2-low metastatic breast cancer where applicable
starsTriple-Negative Breast Cancer
  • arrow_rightPembrolizumab-based treatment in triple-negative breast cancer
  • arrow_rightChemotherapy protocols for advanced triple-negative disease
  • arrow_rightCapivasertib plus paclitaxel and other investigational approaches in eligible patients

Young-Age and Premenopausal Breast Cancer

Dedicated focus on the unique clinical and treatment considerations for younger women and premenopausal patients with breast cancer.

starsPremenopausal Breast Cancer Management
  • arrow_rightOvarian function suppression in combination with systemic therapy
  • arrow_rightTreatment strategies for premenopausal HR-positive metastatic disease
  • arrow_rightBRCA-associated breast cancer management research
Clinical Focus Areas
check_circleMetastatic Breast Cancer
check_circleHR-Positive / HER2-Negative Breast Cancer
check_circleHER2-Positive Breast Cancer
check_circleTriple-Negative Breast Cancer
check_circlePremenopausal and Young-Age Breast Cancer
check_circleClinical Trial-Based Treatment Planning
medical_services

Procedures Performed

Clinical treatment services and research-integrated care approaches for breast cancer at Samsung Medical Center

Prof. Park provides systemic oncology care for breast cancer patients, including chemotherapy, endocrine therapy, CDK4/6 inhibitor-based regimens, anti-HER2 therapy, and participation in clinical trials. Her role as Director of the Clinical Trial Centre means eligible patients may be considered for investigational treatment options.

Medical Oncology โ€“ Breast Cancer

Medical Oncology

Systemic treatment planning and administration for all major breast cancer subtypes.

Systemic Treatment Options
arrow_rightChemotherapy protocols for breast cancer
arrow_rightEndocrine therapy and ovarian function suppression strategies
arrow_rightCDK4/6 inhibitor-based combination regimens
arrow_rightAnti-HER2 therapy and antibody-drug conjugates
arrow_rightImmunotherapy for eligible triple-negative breast cancer patients

Targeted Therapy

Targeted Therapy

Biomarker-guided treatment approaches using modern targeted and precision oncology agents.

Targeted and Precision Approaches
arrow_rightMolecularly guided treatment planning based on pathology and biomarker results
arrow_rightPalbociclib and CDK4/6 inhibitor combinations where indicated
arrow_rightTrastuzumab deruxtecan and HER2-targeted agents
arrow_rightBRCA mutation-informed treatment considerations

Clinical Trial Evaluation

Complex Disease

Evaluation for clinical trial eligibility and investigational treatment access at Samsung Medical Center's Clinical Trial Centre.

Trial Access and Assessment
arrow_rightEligibility assessment for breast cancer clinical trials
arrow_rightInvestigational therapy options for advanced or refractory breast cancer
arrow_rightParticipation in academic and industry-sponsored breast cancer trials

Second Opinion

Second Opinion

Review of pathology, imaging, prior treatment history, and molecular findings for second-opinion consultations in breast cancer.

Second Opinion Consultation
arrow_rightPathology and molecular report review for breast cancer
arrow_rightTreatment plan evaluation for metastatic or complex breast cancer cases
arrow_rightAssessment of clinical trial options and novel therapy eligibility
menu_book

Research & Publications

Peer-reviewed contributions and clinical trial leadership in breast cancer oncology

Prof. Yeon Hee Park is one of the most prolific breast cancer researchers in South Korea. Sungkyunkwan University attributes 389 research outputs to her profile, with an h-index of 63 and more than 26,000 citations. Her research spans the full spectrum of modern breast cancer treatment, from endocrine therapy and CDK4/6 inhibitors to antibody-drug conjugates and genomic breast cancer biology.

Selected Publications
arrow_rightYoung-PEARL Study โ€“ Randomised phase II trial of palbociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal HR-positive, HER2-negative metastatic breast cancer; updated survival results presented at 2024 ASCO Annual Meeting
arrow_rightWhole-genome landscapes of 1,364 breast cancers โ€“ Listed among Prof. Park's 2025 research outputs by Sungkyunkwan University
arrow_rightTrastuzumab deruxtecan research in breast cancer โ€“ Multiple recent publications covering HER2-positive and HER2-low metastatic disease
arrow_rightSacituzumab govitecan in breast cancer โ€“ Contributing author on recent clinical studies
arrow_rightCapivasertib plus paclitaxel in breast cancer โ€“ Listed recent publication (Sungkyunkwan University research profile)
arrow_rightPembrolizumab in triple-negative breast cancer โ€“ Research contributions to immunotherapy in TNBC
arrow_rightBRCA-associated breast cancer โ€“ Publication activity in hereditary and genomic breast cancer research
Clinical Trial Leadership
arrow_rightPrincipal Investigator / Responsible Party โ€“ Palbociclib plus exemestane and GnRH agonist vs capecitabine in premenopausal HR-positive, HER2-negative metastatic breast cancer (NCT02592746); Samsung Medical Center listed as sponsor (ClinicalTrials.gov)
arrow_rightDirector, Clinical Trial Centre โ€“ Samsung Medical Center, 2021 to present; overseeing the clinical research programme across oncology departments
Research Profile

Prof. Park's full publication list is available on PubMed and via her Sungkyunkwan University research profile (ORCID: 0000-0003-4156-9212). A more detailed list may be provided on request.

school

Education & Training

Prof. Park completed her medical degree at Ewha Women's University College of Medicine and her postgraduate training at Kyung Hee University and Korea Cancer Center Hospital. She undertook postdoctoral fellowships at UCSD Cancer Center and the Sidney Kimmel Cancer Center in San Diego, USA.

Undergraduate
M.D.
Ewha Women's University College of Medicine, Seoul, South Korea
1987 โ€“ 1993
Internship
Internship
Korea Cancer Center Hospital
1993 โ€“ 1994
Postgraduate
Residency, Internal Medicine
Korea Cancer Center Hospital
1994 โ€“ 1998
Postgraduate
Master of Science (Medicine)
Kyung Hee University Graduate School, Seoul, South Korea
1996 โ€“ 1998
Fellowship
Fellowship, Haematology-Oncology
Korea Cancer Center Hospital
1998 โ€“ 1999
Doctorate
Ph.D. in Medicine
Kyung Hee University Graduate School, Seoul, South Korea
1999 โ€“ 2000
Postdoctoral Fellowship
Postdoctoral Fellow
UCSD Cancer Center, San Diego, USA
2006
Postdoctoral Fellowship
Postdoctoral Fellow
Sidney Kimmel Cancer Center, San Diego, USA
2006 โ€“ 2007
work_history

Clinical Experience

Prof. Park began her clinical career at Seoul Adventist Hospital and Korea Cancer Center Hospital before completing postdoctoral research in the United States. She joined Samsung Medical Center and Sungkyunkwan University School of Medicine in 2008, progressing to full Professor in 2014. She has held successive leadership roles in breast cancer care and clinical research, and currently serves as Director of the Clinical Trial Centre.

Professor, Department of Hematology-Oncology; Director, Clinical Trial Centre
Samsung Medical Center
Sungkyunkwan University School of Medicine / Breast Cancer Centre
check_circleBreast cancer medical oncology
check_circleMetastatic and advanced breast cancer management
check_circleCDK4/6 inhibitor and endocrine therapy research
check_circleClinical trial design and investigational therapy access
check_circlePremenopausal and young-age breast cancer
check_circleMultidisciplinary breast cancer programme leadership
language

Languages & International

Prof. Park consults in the following languages.

๐Ÿ‡ฌ๐Ÿ‡งEnglish
๐Ÿ‡ฐ๐Ÿ‡ทKorean
Interpreter Support Available

CancerFax can coordinate professional medical interpreter support for international patients consulting at Samsung Medical Center.

CancerFax can coordinate professional medical interpreter support for international patients where required.

support_agentHow CancerFax Helps

How CancerFax Helps You Access Dr. Yeon Hee Park

CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Yeon Hee Park's team โ€” with full coordination from initial inquiry to consultation.

description

Medical Report Review

Free review of your pathology results, imaging, molecular profiling, and treatment history โ€” prepared as a structured clinical summary for Dr. Yeon Hee Park's team.

medical_services

Treatment Eligibility Screening

CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Yeon Hee Park before you travel, so you arrive with a clear pathway.

send

Case Submission

We coordinate direct case submission to Dr. Yeon Hee Park's department, including all documentation required for clinical review and appointment scheduling.

calendar_month

Appointment & Consultation Coordination

CancerFax manages appointment scheduling with Dr. Yeon Hee Park's team, confirming availability and aligning timelines with your travel plans.

flight_takeoff

Travel, Visa & Logistics Support

We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.

support_agent

Follow-Up & Continuity of Care

After your consultation or treatment, CancerFax facilitates communication between Dr. Yeon Hee Park's team and your home oncologist for seamless post-treatment follow-up.

quiz

Frequently Asked Questions About Prof. Yeon Hee Park

Prof. Yeon Hee Park specialises in breast cancer medical oncology within the Department of Hematology-Oncology at Samsung Medical Center, Seoul. Samsung Medical Center lists her specialty group as the Breast Cancer Centre and her clinical expertise as breast cancer.

Prof. Park's verified clinical focus covers hormone receptor-positive breast cancer (including HR-positive, HER2-negative disease), HER2-positive breast cancer, triple-negative breast cancer, and premenopausal or young-age breast cancer. She has particular expertise in advanced and metastatic breast cancer management.

Samsung Medical Center maintains an English-language international patient services infrastructure and lists international appointment contact details on its English-language doctor profiles. CancerFax can assist international patients in organising medical records, preparing structured case summaries, and coordinating the consultation process with the hospital, subject to availability and case acceptance.

Submit your medical reports through CancerFax. The CancerFax team will review the documents, prepare a structured case summary, and coordinate the next steps with Samsung Medical Center on your behalf, subject to the hospital's availability and case review process.

A second-opinion request can be submitted through CancerFax with the patient's pathology reports, imaging, treatment history, molecular findings, and relevant test results. The final consultation format, timeline, and availability depend on Samsung Medical Center's appointment process. CancerFax will coordinate the submission and follow up on your behalf.

Yes. Prof. Park currently serves as Director of the Clinical Trial Centre at Samsung Medical Center. She is the principal investigator of the Young-PEARL study, a clinical trial evaluating palbociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal HR-positive, HER2-negative metastatic breast cancer (NCT02592746). Updated survival results from this study were presented at the 2024 ASCO Annual Meeting.

sendGet Expert Oncology Guidance

Connect with Yeon Hee Park Today

Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.

Free case review ยท No commitment ยท Response within 24 hours ยท Available in 12+ languages

Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.

upload_fileUpload ReportschatWhatsApp